ORKA — Oruka Therapeutics, Inc. stock price, charts and financials

QT91Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
94.96
-2.77-2.83%
OverviewShort InterestFilings
ORKAQT91Oruka Therapeutics, Inc.·NASDAQ
94.96-2.83%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
LGND-0.42%$283.49TVTX-3.06%$62.76MIRM-7.07%$91.83SRRK-4.83%$46.65PTCT-3.87%$65.37CRSP-1.34%$56.56DNTH-4.26%$96.81COGT-5.09%$31.50
Snapshot
Index-P/E-EPS (ttm)-Insider Own18.05%Shs Outstand60.31MPerf Week2.79%
Market Cap5.73BForward P/E-EPS next Y-2.81Insider Trans-36.17%Shs Float50.80MPerf Month-13.43%
Enterprise Value5.46BPEG-EPS next Q-0.60Inst Own-Short Float15.34%Perf Quarter31.27%
Income-127.72MP/S0.00EPS this Y-Inst Trans-Short Ratio6.43Perf Half Y144.62%
Sales0.00P/B5.36EPS next Y-17.85%ROA-11.66%Short Interest7.79MPerf YTD213.30%
Book/sh-P/C-EPS next 5Y-ROE-20.76%52W High115.52 -17.80%Perf Year485.81%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-13.88%52W Low14.89 537.74%Perf 3Y293.70%
Dividend Est.19.36 (20.38%)EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility4.52% 5.14%Perf 5Y159.45%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM59.32%Oper. Margin0.00%ATR (14)4.96Perf 10Y-84.94%
Dividend Ex-DateAug 29, 2024Quick Ratio38.51Sales Y/Y TTM-Profit Margin0.00%RSI (14)48.98Recom2.00
Dividend Gr. 3/5Y-Current Ratio38.51EPS Q/Q-19.57%SMA20-0.22%Beta-0.43Target Price149.56
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-1.38%Rel Volume1.73Prev Close97.73
Employees68LT Debt/Eq0.00EarningsNov 11SMA20055.38%Avg Volume1.12MPrice94.96
IPO DateAug 08, 1997Option/ShortYes / YesEPS/Sales Surpr.-7.32% -Net Debt/EBITDA1.88Volume1,943,005Change-2.83%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-03-26ReiteratedMizuho Securities$120
Jul-01-26ReiteratedUBSBuy$100 → $130
Jun-02-26ReiteratedPiper Sandler$75 → $180
Apr-30-26ReiteratedLeerink PartnersOutperform$109 → $120
Apr-29-26ReiteratedHC Wainwright & Co.Buy$40 → $120
Apr-28-26ReiteratedUBSBuy$50 → $100
Apr-27-26ReiteratedWedbushOutperform$85 → $165
Apr-27-26ReiteratedGuggenheimBuy$125 → $200
Apr-27-26ReiteratedBTIGBuy$73 → $151
Apr-15-26ReiteratedWedbushOutperform$45 → $85
Latest News· Times ET
Sep-09-26
Sep-09-2612:01PM
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conferenceglobenewswire.com
Sep-03-26
Sep-03-2602:17AM
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price TargetBenzinga
Aug-28-26
Aug-28-2608:11AM
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Knowzacks.com
Aug-27-26
Aug-27-2603:09PM
THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)SeekingAlpha
Aug-24-26
Aug-24-2611:55PM
BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKAdefenseworld.net
12:01PM
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officerglobenewswire.com
Aug-21-26
Aug-21-2612:21PM
Oruka Therapeutics Files Prospectus For Offering $1B Mixed ShelfBenzinga
Aug-11-26
Aug-11-2606:46AM
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026zacks.com
06:28AM
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price TargetBenzinga
Aug-10-26
Aug-10-2603:19AM
Oruka Therapeutics Q2 EPS $(0.55) Misses $(0.51) EstimateBenzinga
03:03AM
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com
Aug-03-26
Aug-03-2601:40PM
Oruka Therapeutics Is Priced For Perfection - It's Time To Cash OutSeekingAlpha
Jul-10-26
Jul-10-2611:58AM
Oruka Therapeutics - Intriguing Long Acting Psoriasis Programs May Need Further DeriskingSeekingAlpha
Jul-01-26
Jul-01-2610:30PM
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million SharesBenzinga
Jun-27-26
Jun-27-2611:28AM
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Meanfool.com
Company

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit
000——————
Selling, General and Administrative Excl. Other21136——————
Research and Development101751——————
Other Operating Expense
000——————
Operating Income-122-88-7——————
Interest Expense010——————
Unusual Expense
—————————
Non-Operating Income (Expense)1762——————
Net Income Before Taxes-105-84-5——————
Income Taxes
000——————
Consolidated Net Income-105-84-5——————
Net Income From Continuing Operations-105-84-5——————
Net Income-105-84-5——————
EPS (Recurring)-2.31-4.99-4.44——————
EPS (Basic, Before Extraordinaries)-2.31-4.99-4.44——————
EPS (Diluted)-2.31-4.99-4.44——————
EBITDA-105-82-5——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding461714——————
Market Capitalization1,394330286——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$128.08$95.57$63.06$30.56$-1.95● Close Price0.00M75.48M150.97M226.45M301.94MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Goncalves JoanaChief Medical OfficerSep 15 '26Sale92.387,947734,14531,771Sep 15
Goncalves JoanaChief Medical OfficerSep 15 '26Option Exercise7.327,00051,24039,718Sep 15
Agarwal ArjunSenior Vice President, FinanceSep 15 '26Sale95.7156053,59814,752Sep 15
Klein Lawrence OttoChief Executive OfficerSep 15 '26Sale95.712,452234,681923,128Sep 15
Quinlan Paul TGeneral CounselSep 15 '26Sale95.711,03999,44329,995Sep 15
Sandler Laura LeeChief Operating OfficerSep 15 '26Sale95.7190686,713235,478Sep 15
Agarwal ArjunSenior Vice President, FinanceSep 11 '26Sale92.239,459872,41315,312Sep 15
Agarwal ArjunSenior Vice President, FinanceSep 11 '26Option Exercise15.889,459150,17524,771Sep 15
Klein Lawrence OttoChief Executive OfficerSep 01 '26Option Exercise7.8075,000585,0001,000,580Sep 01
Sandler Laura LeeChief Operating OfficerSep 01 '26Option Exercise7.805,00039,000241,384Sep 01
Sandler Laura LeeChief Operating OfficerSep 01 '26Sale91.825,000459,102236,384Sep 01
Klein Lawrence OttoChief Executive OfficerSep 01 '26Sale91.8375,0006,887,484925,580Sep 01
Goncalves JoanaChief Medical OfficerAug 17 '26Option Exercise7.327,00051,24039,718Aug 17
Goncalves JoanaChief Medical OfficerAug 17 '26Sale111.847,000782,88232,718Aug 17
Quinlan Paul TGeneral CounselAug 14 '26Option Exercise11.6052,000603,00083,034Aug 14
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.